Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
0.3847
+0.0057 (1.50%)
At close: Oct 13, 2025, 4:00 PM EDT
0.4000
+0.0153 (3.98%)
Pre-market: Oct 14, 2025, 5:39 AM EDT
Co-Diagnostics Revenue
Co-Diagnostics had revenue of $162.91K in the quarter ending June 30, 2025, a decrease of -93.87%. This brings the company's revenue in the last twelve months to $1.00M, down -89.02% year-over-year. In the year 2024, Co-Diagnostics had annual revenue of $3.92M, down -42.53%.
Revenue (ttm)
$1.00M
Revenue Growth
-89.02%
P/S Ratio
12.13
Revenue / Employee
$7,603
Employees
132
Market Cap
18.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.92M | -2.90M | -42.53% |
| Dec 31, 2023 | 6.81M | -27.41M | -80.09% |
| Dec 31, 2022 | 34.22M | -63.67M | -65.04% |
| Dec 31, 2021 | 97.89M | 23.33M | 31.30% |
| Dec 31, 2020 | 74.55M | 74.34M | 34,579.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CODX News
- 21 hours ago - Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit - PRNewsWire
- 13 days ago - Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30 - PRNewsWire
- 25 days ago - Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 26 days ago - Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 4 weeks ago - Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains - PRNewsWire
- 4 weeks ago - Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit - PRNewsWire
- 2 months ago - Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C. - PRNewsWire
- 2 months ago - Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha